---
layout: default
title: Lactic Acid
parent: 僅模型預測 (L5)
nav_order: 421
evidence_level: L5
indication_count: 5
---

# Lactic Acid
{: .fs-9 }

證據等級: **L5** | 預測適應症: **5** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Lactic Acid: From Undocumented Original Indication to Atypical Coarctation of Aorta

## One-Sentence Summary

Lactic Acid (DrugBank DB04398) is marketed in Malaysia under 7 registrations, but no original approved indication text was returned in this data pull. The TxGNN model's top-ranked prediction is **Atypical Coarctation of Aorta** (score 99.59%), but this specific prediction has **zero supporting clinical trials and zero literature**, and the model's own rationale states there is no known biological mechanism by which lactic acid could affect this congenital structural defect.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no approved indication text on file for any of the 7 NPRA registrations |
| Predicted New Indication | Atypical Coarctation of Aorta |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Mechanism of action data is not available for lactic acid in this evidence pack.

For this specific candidate, the evidence pack itself concludes the prediction is **not** mechanistically reasonable: atypical coarctation of the aorta is a structural congenital malformation, and lactic acid — a small-molecule metabolite — has no known mechanism to repair or remodel anatomical structure. The high TxGNN score (99.59%) appears to reflect a graph-level association (e.g. shared nodes/co-occurrence in the knowledge graph) rather than a genuine pharmacological or clinical relationship. No clinical trials or literature were found to support this specific drug–disease pairing.

Note that lower-ranked predictions in this pack fared somewhat better on evidence: rank 2 ("aortic malformation") surfaced 9 trials and 20 publications, but reviewers judged all of them as node co-occurrence rather than genuine mechanistic support (lactate appears there only as a perfusion/ischemia biomarker, not a treatment). Rank 5 ("dry eye syndrome") reached decision stage S1 ("Research Question") — lactic acid has plausible relevance there as a humectant excipient in some artificial tear formulations, though literature also shows lactate signaling can *promote* inflammation in Sjögren's-type dry eye, so the mechanistic direction is unresolved.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Malaysia Market Information

NPRA records show 7 active registrations for Lactic Acid (market status: 已上市 / Marketed), but license-level details (license number, product name, dosage form, manufacturer, approved indication text) were not returned in this data pull — all fields came back empty. This needs to be re-queried from the NPRA source before any regulatory comparison can be made.

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: TFDA/NPRA label warnings and contraindications are flagged as a Blocking data gap (DG001) — this must be resolved before any safety screening (S1) can proceed for this drug, regardless of which indication is pursued.)*

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (Atypical Coarctation of Aorta) has no clinical trials, no literature, and an explicitly acknowledged lack of mechanistic plausibility — it is an L5, model-prediction-only signal that should not advance. Regulatory safety data is also a Blocking gap, so this candidate cannot yet clear even an initial safety screen.

**To proceed, the following is needed:**
- TFDA/NPRA package insert (warnings, contraindications) — Blocking gap (DG001)
- Drug mechanism of action (MOA) data via DrugBank — High-priority gap (DG002)
- NPRA license-level details (product names, dosage forms, approved indications) for the 7 existing registrations
- If a repurposing signal is still wanted for this drug, re-evaluate rank 5 (dry eye syndrome) instead, which reached S1/"Research Question" status with some biological rationale, rather than the top-ranked but mechanistically unsupported aortic prediction
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

